

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



March 30, 2026

Company name:	Mochida Pharmaceutical Co., Ltd.
Name of representative:	Naoyuki Mochida, Representative Director, President
(Securities code:	4534 Prime Market, TSE)
Inquiries:	Kenichi Miyamoto, Head of Finance & Accounting Department
(Telephone:	+81-3-3358-7211)

Notice Regarding Secondary Offering of Shares

Mochida Pharmaceutical Co., Ltd. (the “Company”) hereby announces that a resolution was adopted by the Board of Directors held on March 30, 2026, in relation to a secondary offering of shares of common stock of the Company (the “Offering”) as follows.

1. Secondary Offering of Shares (Offering by way of Purchase and Underwriting by the Underwriter)

- (1) Class and number of shares to be offered: 1,153,600 shares of common stock of the Company
- (2) Selling shareholders: The lead manager
- (3) Offer price: To be determined.
The offer price will be determined on the Pricing Date (as defined below) in accordance with the method set forth in Article 25 of the Rules Concerning Underwriting, Etc. of Securities of the Japan Securities Dealers Association, after considering market demand, based on the preliminary pricing range calculated by multiplying the closing price of the regular trading of the shares of common stock of the Company on the Tokyo Stock Exchange, Inc. on a certain date between Monday, April 6, 2026 and Thursday, April 9, 2026 (the “Pricing Date”) (or, if no closing price is recorded on the Pricing Date, the closing price on the day immediately preceding the Pricing Date) by a factor between 0.90 and 1.00 (with any fraction less than one yen being rounded down to the nearest whole yen).
- (4) Offering method: The offering will be made through a secondary offering by way of purchase and underwriting by the underwriters (the “Underwriters”). The aggregate amount of the difference between the offer price and the subscription price (equivalent to the purchase price per share paid to the selling shareholders by the Underwriters) will be retained by the Underwriters as commission.

- (5) Delivery date: The fifth business day following the Pricing Date
- (6) The lead manager will conduct a secondary offering of 1,153,600 shares of common stock of the Company, which will be purchased from the shareholders of the Company, Taisho Pharmaceutical Holdings Co., Ltd. and Sumitomo Pharma Co., Ltd.
- (7) Offer price and any other matters required for the Offering by way of purchase and underwriting by the Underwriters shall be approved at the sole discretion of Representative Director and Senior Executive Managing Officer.

2. Secondary Offering of Shares (Offering by way of Over-allotment)

- (1) Class and number of shares to be offered: Up to 173,000 shares of common stock of the Company
The above-mentioned number of shares to be offered represents the maximum number of shares to be offered, and the actual number of shares to be offered may decrease, or the Offering by way of over-allotment itself may not be carried out at all, subject to market demand. The number of shares to be offered will be determined on the Pricing Date, after considering market demand and other conditions.
- (2) Selling shareholder: The lead manager
- (3) Offer price: To be determined.
The offer price will be determined on the Pricing Date. The offer price will be the same as the offer price in the Offering by way of purchase and underwriting by the Underwriters.
- (4) Offering method: In connection with the Offering by way of purchase and underwriting by the Underwriters, the lead manager will, after considering market demand and other conditions, undertake a secondary offering of shares of common stock of the Company by borrowing no more than 173,000 shares from certain shareholders of the Company.
- (5) Delivery date: Same as that in the Offering by way of purchase and underwriting by the Underwriters.
- (6) Offer price and any other matters required for the Offering by way of over-allotment shall be approved at the sole discretion of Representative Director and Senior Executive Managing Officer.

Disclaimer: This document does not constitute an investment solicitation for any securities for sale. This document does not constitute an offer of investment in nor solicitation for purchase securities within the United States or elsewhere. The securities referred to in this document have not been, and will not be, registered under the U.S. Securities Act of 1933 or any relevant securities law of any state. The securities may not be offered or sold in the United States absent registration or an exemption from registration requirements under the U.S. Securities Act of 1933. No offers of securities for sale in the United States will be made in connection with the above-mentioned transactions.